Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

ABSTRACT:

Importance

Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. Understanding the treatment-related adverse events of these drugs is critical for clinical practice.

Objective

To evaluate the incidences of treatment-related adverse events of PD-1 and PD-L1 inhibitors and the differences between different drugs and cancer types.

Data sources

PubMed, Web of Science, Embase, and Scopus were searched from October 1, 2017, through December 15, 2018.

Study selection

Published clinical trials on single-agent PD-1 and PD-L1 inhibitors with tabulated data on treatment-related adverse events were included.

Data extraction and synthesis

Trial name, phase, cancer type, PD-1 and PD-L1 inhibit

SUBMITTER: Wang Y 

PROVIDER: S-EPMC6487913 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature